These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 24971315)

  • 21. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
    Saad F; Markus R; Goessl C
    BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histopathological assessment of prostate cancer bone osteoblastic metastases.
    Roudier MP; Morrissey C; True LD; Higano CS; Vessella RL; Ott SM
    J Urol; 2008 Sep; 180(3):1154-60. PubMed ID: 18639279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanisms of bone metastasis formation].
    Peyruchaud O
    J Soc Biol; 2007; 201(3):229-36. PubMed ID: 18157074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
    Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone.
    Jin R; Sterling JA; Edwards JR; DeGraff DJ; Lee C; Park SI; Matusik RJ
    PLoS One; 2013; 8(4):e60983. PubMed ID: 23577181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
    Futakuchi M; Fukamachi K; Suzui M
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of osteoblastic bone metastasis of prostate cancer].
    Yonou H; Ogawa Y; Ochiai A
    Clin Calcium; 2006 Apr; 16(4):557- 64. PubMed ID: 16582505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Models of Prostate Cancer Bone Metastasis.
    Park SH; Eber MR; Shiozawa Y
    Methods Mol Biol; 2019; 1914():295-308. PubMed ID: 30729472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone imaging in prostate cancer.
    Dotan ZA
    Nat Clin Pract Urol; 2008 Aug; 5(8):434-44. PubMed ID: 18682719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Kollmeier M; McBride S; Yamada Y; Zelefsky MJ
    J Urol; 2015 Dec; 194(6):1624-30. PubMed ID: 26165583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic process of prostate cancer metastasis to bone.
    Tantivejkul K; Kalikin LM; Pienta KJ
    J Cell Biochem; 2004 Mar; 91(4):706-17. PubMed ID: 14991762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.
    Araujo A; Cook LM; Lynch CC; Basanta D
    Cancer Res; 2014 May; 74(9):2391-401. PubMed ID: 24788098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.
    Karamanolakis D; Bogdanos J; Sourla A; Milathianakis C; Tsintavis A; Lembessis P; Tenta R; Tiblalexi D; Koutsilieris M
    Mol Med; 2002 Nov; 8(11):667-75. PubMed ID: 12520083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total and regional bone mass in metastatic cancer of the prostate.
    Rico H; Chapado MS; Revilla M; Bethencourt F; Villa LF; Guil M
    Eur Urol; 1996; 30(1):73-6. PubMed ID: 8854071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
    Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.